Edgar Filing: Sanofi - Form 6-K

Sanofi Form 6-K March 29, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2018

Commission File Number: 001-31368

SANOFI

(Translation of registrant s name into English)

54, rue La Boétie, 75008 Paris, FRANCE

Edgar Filing: Sanofi - Form 6-K

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.		
	Form 20-F	Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule $101(b)(1)$:		
Indicate by check mark if the registrant is 101(b)(7):	s submitting the Form	6-K in paper as permitted by Regulation S-T Rule
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.		
	Yes	No
If Yes marked, indicate below the file 82	number assigned to the	e registrant in connection with Rule 12g3-2(b):

In March 2018, Sanofi issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

Exhibit List

Exhibit No. Description

Exhibit 99.1 Press release dated March 29, 2018: EMA to review sotagliflozin as potential treatment for type 1

diabetes

Exhibit Index

Exhibit No. Description

Exhibit 99.1 Press release dated March 29, 2018: EMA to review sotagliflozin as potential treatment for type 1

diabetes

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 29, 2018 SANOFI

By /s/ Alexandra Roger Name: Alexandra Roger

Title: Head of Securities Law and

Capital Markets

4